ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2023
The Role of Pretherapy Quantitative Imaging and Dosimetry in Radioiodine Therapy for Advanced Thyroid Cancer.
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 16 citations in OpenAlex.
- Results of the SEL-I-METRY Phase II Trial on Resensitization of Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine Therapy.Thyroid : official journal of the American Thyroid Association · 2023Trial
- Dosimetry inJournal of clinical medicine · 2026Review
- Theranostic Approaches to Radioiodine-Refractory Differentiated Thyroid Cancer: A Narrative Review.Cancers · 2026Review
- MAPK pathway inhibitors enhance radioiodine sensitivity in anaplastic thyroid carcinoma through promoting NIS expression and ARF4-mediated NIS membrane transport.Scientific reports · 2026Article
- Quantitative SPECT/CT: Technique and Clinical Applications.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026Review
- BRAF V600E in thyroid cancer: navigating prognostic uncertainty and therapeutic opportunity.European thyroid journal · 2025Review
- Reigniting the Flame for Redifferentiation Strategies in Differentiated Thyroid Cancers: Journey of Tyrosine Kinase Inhibitors to Renewed Radioactive-Iodine Avidity.Endocrinology and metabolism (Seoul, Korea) · 2025Article
- Redifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer: an International Thyroid Oncology Group statement.The lancet. Diabetes & endocrinology · 2025Review
- Radioiodine-refractory thyroid cancer-is it time to change the definition in light of novel redifferentiation therapies?European journal of nuclear medicine and molecular imaging · 2025Article
- Improvements ofEJNMMI physics · 2024Article
- Systemic Immune-Inflammation Index and Systemic Inflammation Response Index Predict the Response to Radioiodine Therapy for Differentiated Thyroid Cancer.Journal of inflammation research · 2024Article
- Rapid predictive dosimetry for Second Strike prescription based on whole body radioiodine kinetics in differentiated thyroid cancer.Asia Oceania journal of nuclear medicine & biology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 5 institutions in 1 country.
Funding
Abstract
Radioactive iodine is well established as a successful treatment for differentiated thyroid cancer (DTC), although around 15% of patients have local recurrence or develop distant metastases and may become refractory to radioactive iodine (RAI). A personalized approach to treatment, based on the absorbed radiation doses delivered and using treatments to enhance RAI uptake, has not yet been developed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.